Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Poseida is a clinical-stage biopharmaceutical company building out a wholly-owned pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of haematologoical malignancies, like multiple myeloma, and solid tumours, like prostate cancer.

Poseida is developing two approaches with its next-generation CAR-T therapies: autologous and allogeneic.

Autologous therapies are fully customised treatments created using an individuals patient's own T cells.

In contrast, allogeneic therapies use T cells derived from healthy donors, allowing Poseida to make an off-the-shelf treatment for hundreds or thousands of patients from a single manufacturing run.

Poseida's CAR-T products leverage its piggyBac DNA Modification system to engineer therapeutic T cells. Poseida believes this non-viral approach can result in greater safety, efficacy and versatility when treating different forms of cancer. It also enables Poseida to create therapies that are predominantly comprised of stem memory T cells (TSCM cells) which are a younger, self-renewing type of immune cell that may allow for longer duration of response, less toxicity and the ability to successfully treat solid tumours.

Poseida Pipeline

Candidate

Indication

IND-enabling

Phase 1

Phase 2

Phase 3*

P-BCMA-101
Autologous CAR-T Therapy

Multiple myeloma

P-PSMA-101
Autologous CAR-T Therapy

Castrate-resistant prostate cancer

P-BCMA-ALLO1
Allogeneic CAR-T Therapy

Multiple myeloma

P-MUC1C-101
Autologous CAR-T Therapy

Solid tumours

Candidate: P-BCMA-101
Autologous CAR-T Therapy

Indication: Multiple myeloma

IND-enabling

Phase 1

Phase 2

Phase 3*


Candidate: P-PSMA-101
Autologous CAR-T Therapy

Indication: Castrate-resistant prostate cancer

IND-enabling

Phase 1

Phase 2

Phase 3*


Candidate: P-BCMA-ALLO1
Allogeneic CAR-T Therapy

Indication: Multiple myeloma

IND-enabling

Phase 1

Phase 2

Phase 3*


Candidate: P-MUC1C-101
Autologous CAR-T Therapy

Indication: Solid tumours

IND-enabling

Phase 1

Phase 2

Phase 3*

* Phase 3 may not be necessary if Phase 1/2 can serve as a registrational clinical trial. The FDA has not indicated whether Phase 3 trials will be required for any of our product candidates.